How to REVISIT the increasing “real world” evidence for stroke prevention in non-valvular atrial fibrillation?

Lip, Gregory Y.H.

doi:10.1080/03007995.2016.1254604

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is still no independent confirmation in randomized clinical trials with head-to-head NOACs (Lip, 2016). Considerations for choosing NOACs should be made such as patient's age, stroke risk, bleeding risk, renal function, drug interactions, cost, besides adhesion and preference of patient.…”

Section: Effectiveness and Safety Of Noacsmentioning

confidence: 99%

Pharmacological profile of non-vitamin K antagonist oral anticoagulants

Silva¹

2017

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

female patients, oral anticoagulants are recommended, and considering shared decision between doctor and patient. However, they are contraindicated in patients with mechanical prosthetic valve and in patients with moderate-to-severe mitral stenosis and atrial fibrillation. They have also been approved for prevention and treatment of deep vein thrombosis and pulmonary embolism. Dabigatran, a direct thrombin inhibitor, was the first to be approved, followed by the factor Xa inhibitors, rivaroxaban, apixaban, and recently, in 2015, edoxaban. They have advantages such as the use of fixed-dose, with infrequent drug interaction, rapid onset of action and do not require monitoring of their anticoagulant action. Nonetheless, they have different half-lives, the need for dose adjustment according to renal function, weight and age of the patient. Its use in pregnant women and children or adolescents is not well established. There are also peculiarities about the risks of bleeding, effects on coagulation tests and specific antidotes. Through this review we discuss the pharmacokinetics and pharmacodynamics characteristics of direct oral anticoagulants, its indications, interactions and contraindications. Analysis of its efficacy, safety and risk-benefit ratio will also be addressed.

show abstract

Section: Effectiveness and Safety Of Noacsmentioning

confidence: 99%